NMRA

0.310010.66%
DS

Daljit Singh Aurora

Chief Operationg & Development officer

Dr. Daljit Singh Aurora, also known as Bill, is Chief Operationg and development officer of Neumora Therapeutics, Inc. from February 14, 2025. Dr. Aurora was Chief Strategy Officer of Neumora Therapeutics, Inc. from January 2023 to February 14, 2025. Dr. Aurora was Chief Corporate Affairs Officer of Neumora Therapeutics, Inc. from August 2021 to December 2022. Dr. Aurora joined the Neumora Therapeutics, Inc. in 2021. He has deep expertise in global medical affairs and corporate strategy, as well as a demonstrated track record of success in launching over many products across biologics and small molecules and therapeutic areas including neuropsychiatry, oncology, rheumatology, dermatology and nephrology. He served as Chief Corporate Affairs Officer at Neumora Therapeutics, Inc. since August 2021 until December 2022. Dr. Aurora was Chief Scientific Affairs Officer at Dermira, Inc. He served as Senior Vice President for Medical Affairs at Dermira, Inc. since joining in 2016. Dr. Aurora served as Vice President of Medical Affairs at Neurocrine Biosciences Inc. since May 04, 2015. Prior to joining Neurocrine, Dr. Aurora was Vice President, Global Center for Scientific Affairs at Merck. Prior to Merck, he spent twelve years at Amgen as the Vice President of Global Scientific Affairs where he lead the Regional Medical Liaisons, Medical Communications, Medical Information, Medical Writing and Scientific Affairs Training and Development groups across therapeutic areas and geographies. He has also held positions at Novartis and Bristol Myers Squibb. He is also Board Certified in Psychiatric Pharmacy Practice (BCPP). Dr. Aurora received his B.S. in Pharmacy from the University of Texas at Austin, his Doctor of Pharmacy and Clinical Residency in Psychopharmacy from the University of Texas Health Science Center at San Antonio.

Positions